19:30:49 EDT Sun 09 Aug 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Yield Growth Corp (The)
Symbol BOSS
Shares Issued 105,266,019
Close 2019-12-09 C$ 0.24
Recent Sedar Documents

Yield files for patent for weight loss mushrooms

2019-12-10 07:24 ET - News Release

Ms. Penny White reports

YIELD GROWTH SUBSIDIARY FLOURISH MUSHROOM LABS FILES FOR U.S. PATENT TO USE SEROTONIN ANTAGONISTS FROM PSYCHEDELIC MUSHROOMS FOR WEIGHT LOSS

The Yield Growth Corp.'s subsidiary, Flourish Mushroom Labs, has filed a U.S. provisional patent application in the United States for the invention relating to methods of using serotonin antagonists, in particular, psychedelic mushroom actives, for weight loss.

The Flourish Mushroom Labs pending patent seeks to protect the invention that administration of psilocin and/or psilocybin results in an overall weight loss in individuals by reducing food cravings, counteracting compulsive overeating and aiding in improving quality of diet by altering food choices. The patent pending covers the use of microdose administration of psilocin/psilocybin to have the additional weight loss effect of increasing metabolism, which, combined with a decrease in food cravings or compulsive overeating, or altering food choices to less calorie dense foods, could result in substantial and beneficial weight loss. The Flourish Mushroom Labs pending patent also covers the use of psilocin/psilocybin in treatment or regulation of diabetes, and regulation of blood glucose and to reduce susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus and other illnesses associated with obesity.

Obesity has been formally recognized by the World Health Organization as a global epidemic. Over 35 per cent of adults in the United States, and more than 500 million adults worldwide, are categorized as obese. Obesity is expected to cause or contribute to hundreds of thousands of deaths per year in the United States alone. Obesity reduces life expectancy, increases susceptibility to other disease states such as cardiovascular disease, high blood pressure, diabetes mellitus, hypertension, multiple sclerosis, erectile dysfunction, urinary incontinence, chronic renal failure, sleep apnea, asthma and many forms of cancer. In addition to the clinically defined obese (those with a body mass index (in kilograms per cubic metre) of greater than 30), a large percentage of the population, while not obese, are overweight. Obesity and overweightness are a leading preventable cause of death worldwide.

In most cases, obesity and overweightness is caused by a food energy intake that exceeds energy use. Unfortunately, decreasing caloric intake can be very difficult for many people. The dieting industry is enormous, with some estimates showing that Americans spend over $60-billion annually on diet and weight loss products. Unfortunately, many of these diets do not work long term. One theory for this is because it is not enough to temporarily change food intake; rather, an individual's behaviour needs to change for long-term success.

Quality of diet also has a significant impact on obesity and overweightness, with low caloric content foods such as green vegetables contributing less to obesity than calorie dense foods which have high calories for their volume, such as refined carbohydrates. Interestingly, human food preferences (such as preferences for certain types of food) have been linked with a 5-HT2A serotonergic receptor polymorphism (Prado-Lima et al., Mol Psychiatry October, 2006).

Psilocin/psilocybin is known as 5-HT2A agonists or partial agonists. Psilocin has no approved or common medical use. However, the Heffter Research Institute has published research indicating that psilocybin can relieve the symptoms of anxiety and depression often found in patients with a cancer diagnosis, as well as for treatment of addiction and obsessive-compulsive disorder. Usona Institute is currently in the planning phase for a phase 2/3 clinical research program on use of psilocybin as a treatment for major depressive disorder.

The U.S. provisional patent application provides a right of priority under the Paris Convention as well as the Patent Cooperation Treaty. This means it establishes an effective filing date for inventions adequately described within it for PCT applications or applications in more than 170 countries who are members of the Paris Convention, as long as the foreign application is filed within one year of the provisional filing date.

About Flourish Mushroom Labs Inc.

Created and incubated by the team at Yield Growth, Flourish Mushroom Labs aims to be a leader in the fast growing functional foods market -- and improve life by offering high-quality mushroom-infused products. Flourish Mushroom Labs is also conducting research into potentially therapeutic benefits of compounds found in psychedelic mushrooms. Flourish Mushroom Labs is a majority-owned subsidiary of Yield Growth.

About The Yield Growth Corp.

Yield Growth is developing cannabis and edible mushroom products and conducting research into uses, methods and products that improve life in what the Global Wellness Institute reports is a $4.2-trillion wellness market. It owns the cannabis wellness brands Urban Juve, Wright & Well, and Jack n Jane. The Yield Growth management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, M.A.C Cosmetics, Skechers and Aritzia. Its all natural hemp skin care brand, Urban Juve, has signed agreements for distribution in Canada, Colombia, Brazil, Costa Rica, Panama, Argentina, El Salvador, Ecuador, Peru, Greece, Cyprus, Bulgaria, Romania and Serbia.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.